Therapeutic strategies for patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid
10.3969/j.issn.1001-5256.2017.11.010
- VernacularTitle:对熊去氧胆酸应答不佳的原发性胆汁性胆管炎治疗策略
- Author:
Yiwen SHI
1
;
Hong YOU
Author Information
1. 首都医科大学附属北京友谊医院肝病研究中心
- Keywords:
cholangitis,biliary;
ursodeoxycholic acid;
chenodeoxycholic acid;
clofibric acid;
glucocrticoids;
antibodies,monoclonal
- From:
Journal of Clinical Hepatology
2017;33(11):2101-2104
- CountryChina
- Language:Chinese
-
Abstract:
In recent years,ursodeoxycholic acid is commonly used for the treatment of primary biliary cholangitis (PBC);however,the growing number of PBC patients and the occurrence of suboptimal response and treatment intolerance pose a great challenge to treatment regimens.The approval of the new drug obeticholic acid brings hope to PBC patients,and a combination of fibrates also has a promising future.More studies are in progress.Although new drugs,such as monoclonal antibody,fibroblast growth factor 19,and sodium-dependent bile acid transporter inhibitor,have limited efficacy data,they provide new directions for the treatment of PBC.With the help of individualized follow-up and stratified therapy,the management of PBC patients will enter a new stage.
